Brandeis would like to spin out a new company to take advantage of an extensive IP portfolio that has been developed over 10 years and $9 million in research funding. Several major companies have expressed interest in the technology if it were further developed. A major company in the industry would like to license the technology for research purposes and potentially for TB diagnostics. This is a platform opportunity with several applications.